Quintrio
Home

Stock overview

Adlai Nortye Group Ltd. American Depositary Shares

ANL

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Last trade $9.47
Day change -$0.56 (-5.58%)
Day range $9.40 – $10.14
Volume 175,165
Market cap $646M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for ANL.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for ANL.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.

GlobeNewswire Inc.

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Adlai Nortye Ltd. (Nasdaq: ANL), a clinical-stage biotechnology company, announced a $150 million private placement of 11.32 million ADSs at $13.25 per share. The oversubscribed offering attracted participation from new institutional investors including Soleus Capital, Perceptive Advisors, and ADAR1 Capital Management, as well as existing investors. The company plans to use proceeds to advance its RAS-targeting therapies and next-generation cancer immunotherapies pipeline.

GlobeNewswire Inc.

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Adlai Nortye Ltd. announced that the first patient has been dosed in the United States in its Phase 1 clinical trial of AN9025, an oral pan-RAS(ON) inhibitor for advanced solid tumors with RAS mutations. The trial is being conducted as a multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., with Adlai Nortye retaining ex-China rights and ASK Pharm holding rights in mainland China, Hong Kong, and Macao.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Aug 13, 2008$0.25Aug 29, 2008unknown
May 14, 2008$0.25May 30, 2008unknown
Feb 13, 2008$0.25Feb 29, 2008unknown
Nov 14, 2007$0.25Nov 30, 2007unknown
Aug 15, 2007$0.25Aug 31, 2007unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.